Retrospective Analysis of Real-World Data for the Treatment of Obstructive Sleep Apnea with Slow Maxillary Expansion Using a Unique Expansion Dental Appliance (DNA).
Level 4 - case-series / case-control
Retrospective case series without a control group
PubMed 37218915 · doi:10.3390/pathophysiology30020017
What was done
A retrospective analysis of real-world data evaluated the effects of a non-surgical slow maxillary expansion device (the Daytime-Nighttime Appliance, or DNA) in patients diagnosed with obstructive sleep apnea (OSA). Assessed outcomes included changes in apnea-hypopnea index (AHI), transpalatal width, airway volume, common modalities, and treatment complications.
What was found
DNA appliance use was associated with a 46% reduction in AHI (p = 0.00001) along with statistically significant increases in transpalatal width and airway volume (p < 0.00001). Overall, 80% of patients experienced some improvement in AHI scores, and 28% had their OSA symptoms completely resolved. Baseline and follow-up absolute numerical values, confidence intervals, and complication rates were not reported in the abstract.
Why it matters
This study reports that non-surgical maxillary expansion using an oral appliance may increase airway volume and decrease apnea severity in OSA. If validated in controlled settings, it could offer an alternative approach to reduce dependence on continuous positive airway pressure or standard mandibular advancement splints.
Limits
The abstract omits sample size (n), participant demographics, absolute volumetric and dimensional measurements, follow-up duration, and specific adverse events. The retrospective, uncontrolled design carries substantial risk of selection and confounding bias and lacks comparison against sham or standard therapies.
Cited by
- partial There is an FDA-approved oral device that treats severe sleep apnea and reduces the Apnea-Hypopnea Index (AHI) to normal levels, putting it into lasting remission.